Gestational trophoblastic neoplasia: An update

Jacqueline M. Morgan, John Robert Lurain III*

*Corresponding author for this work

Research output: Contribution to journalReview article

28 Scopus citations


Gestational trophoblastic neoplasia (GTN) includes invasive mole, choriocarcinoma, and placental site trophoblastic tumors. The overall cure rate in treating these tumors currently exceeds 90%. Thorough evaluation and staging allow selection of appropriate therapy that maximizes chances for cure while minimizing toxicity. Nonmetastatic (stage I) and low-risk metastatic (stages II and III, World Health Organization [WHO] score < 7) GTN can be treated with single-agent chemotherapy, resulting in a survival rate approaching 100%. High-risk metastatic GTN (stage IV, WHO score ≥7) requires initial multiagent chemotherapy with or without adjuvant radiation and surgery to achieve a survival rate of 80% to 90%.

Original languageEnglish (US)
Pages (from-to)497-504
Number of pages8
JournalCurrent oncology reports
Issue number6
StatePublished - Dec 1 2008

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Gestational trophoblastic neoplasia: An update'. Together they form a unique fingerprint.

Cite this